Farrugia A
Department of Laboratory Haematology, Royal Children's Hospital, Parkville, Vic.
Australas Biotechnol. 1993 Jan-Feb;3(1):16-20.
Several excellent reviews have described the role of biotechnological procedures in the production of pharmaceuticals derived from human blood plasma (Meulien and Tuddenham 1990, Brodniewicz-Proba 1991). The system of blood collection and fractionation is driven by the need to manufacture concentrates of coagulation Factor VIII. This review will analyse the effect of biotechnology on the manufacture of this product. The recent advances in Factor VIII purification using novel immunoaffinity and ion-exchange procedures will be described, as will the technology of the production of recombinant Factor VIII. The impact of these technologies on the manufacture of other therapeutic blood fractions as well as on the whole blood industry will be discussed.
已有几篇优秀的综述描述了生物技术程序在生产源自人血浆的药物中的作用（默利安和塔登纳姆，1990年；布罗德涅维茨-普罗巴，1991年）。血液采集和分馏系统是由生产凝血因子VIII浓缩物的需求驱动的。本综述将分析生物技术对该产品生产的影响。将描述使用新型免疫亲和和离子交换程序在因子VIII纯化方面的最新进展，以及重组因子VIII的生产技术。还将讨论这些技术对其他治疗性血液成分的生产以及对整个血液行业的影响。
